Vonoprazan a novel potassium competitive acid blocker; another leap forward.

IF 1.7 Q3 GASTROENTEROLOGY & HEPATOLOGY

Przegla̜d Gastroenterologiczny Pub Date : 2024-01-01 Epub Date: 2024-05-08 DOI:10.5114/pg.2024.139426

Maha Elsabaawy, Ahmed Shaban, Ahmed Ezz Al-Arab, Osama Elbahr, Ahmed Edrees, Sameh Afify

{"title":"Vonoprazan a novel potassium competitive acid blocker; another leap forward.","authors":"Maha Elsabaawy, Ahmed Shaban, Ahmed Ezz Al-Arab, Osama Elbahr, Ahmed Edrees, Sameh Afify","doi":"10.5114/pg.2024.139426","DOIUrl":null,"url":null,"abstract":"Introduction: The eradication rate of Helicobacter pylori (H. pylori) has decreased due to antibiotics resistance and inadequate acid suppression. Vonoprazan is a novel potassium-competitive acid blocker (P-CAB), which has a rapid and sustained acid inhibitory effect and may be more effective than conventional proton pump inhibitors (PPIs) in H. pylori eradication.Aim: to study the efficacy and safety of vonoprazan as a component of first-line H. pylori eradication treatment compared with conventional PPI-based therapy.Material and methods: This randomised (one to one) non-blinded study was conducted on 400 consecutive proven H. pylori infected patients, of whom 200 received vonoprazan-based triple therapy, while 200 patients received PPI-based triple therapy for 14 days. The study outcomes were evaluated as eradication rate and adverse events in both patient groups.Results: The eradication rate was 86% in the vonoprazan group and 74.5% in the PPI group. The vonoprazan eradication rate was significantly higher than that of PPIs (p = 0.004). There was no significant difference regarding adverse events between both patient groups.Conclusions: Vonoprazan-based therapy was more effective than PPI-based therapy as a first-line H. pylori eradication treatment. Vonoprazan was generally safe and well tolerated.","PeriodicalId":20719,"journal":{"name":"Przegla̜d Gastroenterologiczny","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11200074/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Przegla̜d Gastroenterologiczny","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/pg.2024.139426","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The eradication rate of Helicobacter pylori (H. pylori) has decreased due to antibiotics resistance and inadequate acid suppression. Vonoprazan is a novel potassium-competitive acid blocker (P-CAB), which has a rapid and sustained acid inhibitory effect and may be more effective than conventional proton pump inhibitors (PPIs) in H. pylori eradication.

Aim: to study the efficacy and safety of vonoprazan as a component of first-line H. pylori eradication treatment compared with conventional PPI-based therapy.

Material and methods: This randomised (one to one) non-blinded study was conducted on 400 consecutive proven H. pylori infected patients, of whom 200 received vonoprazan-based triple therapy, while 200 patients received PPI-based triple therapy for 14 days. The study outcomes were evaluated as eradication rate and adverse events in both patient groups.

Results: The eradication rate was 86% in the vonoprazan group and 74.5% in the PPI group. The vonoprazan eradication rate was significantly higher than that of PPIs (p = 0.004). There was no significant difference regarding adverse events between both patient groups.

Conclusions: Vonoprazan-based therapy was more effective than PPI-based therapy as a first-line H. pylori eradication treatment. Vonoprazan was generally safe and well tolerated.

查看原文本刊更多论文

新型钾竞争性酸阻断剂 Vonoprazan；又一次飞跃。

导言：由于抗生素耐药和抑酸不足，幽门螺旋杆菌（H. pylori）的根除率有所下降。Vonoprazan是一种新型钾竞争性酸阻滞剂（P-CAB），具有快速、持续的抑酸作用，在根除幽门螺杆菌方面可能比传统质子泵抑制剂（PPI）更有效：这项随机（一对一）非盲法研究对 400 名连续确诊的幽门螺杆菌感染患者进行了研究，其中 200 名患者接受了以 vonoprazan 为基础的三联疗法，而 200 名患者接受了为期 14 天的以 PPI 为基础的三联疗法。研究结果评估了两组患者的根除率和不良反应：结果：Vonoprazan 组的根除率为 86%，PPI 组为 74.5%。Vonoprazan的根除率明显高于PPIs（P = 0.004）。两组患者的不良反应无明显差异：结论：作为根除幽门螺杆菌的一线疗法，沃诺普拉赞疗法比PPI疗法更有效。沃诺普拉赞总体上安全且耐受性良好。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Przegla̜d Gastroenterologiczny GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

2.20

自引率

7.70%

发文量

审稿时长

6-12 weeks

期刊介绍： Gastroenterology Review is a journal published each 2 months, aimed at gastroenterologists and general practitioners. Published under the patronage of Consultant in Gastroenterology and Polish Pancreatic Club.